Grants

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Adolescent Brain Cognitive Development -Extended (ABCD-E) Study-Research Project Sites (U01 Clinical Trial Not Allowed)

National Institutes of Health

Limited Competition for the Adolescent Brain Cognitive Development -Extended (ABCD-E) Study-Research Project Sites (U01 Clinical Trial Not Allowed)

2026-07-09

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Adolescent Brain Cognitive Development -Extended (ABCD-E) Study-Research Project Sites (U01 Clinical Trial Not Allowed)

National Institutes of Health

This is a notice of funding opportunity (NOFO) for a Limited Competition that will invite applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with the National Institutes of Health (NIH) standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered for funding. Only current award recipients will be eligible to apply. This NOFO seeks linked collaborative U01 applications to renew the current Adolescent Brain Cognitive Development (ABCD) Research Project Sites to extend study visits into young adulthood. This renewal, called Adolescent Brain Cognitive Development – Extended (ABCD-E) study, is critical to be able to follow these youth into emerging adulthood, when many of the outcomes of interest (e.g., substance use disorders, mental health disorders, chronic diseases, and other health conditions) will manifest. The structure of the ABCD-E study Consortium shall consist of three highly integrated components: (1) a set of linked Research Project Sites, (2) a single central Data Analysis, Informatics, and Resource Center, and (3) a single overall Coordinating Center. As such, this NOFO runs in parallel with a companion NOFO that solicits applications for two centers (RFA-DA-27-003). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities.

2026-07-09

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health

Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health

This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), are requested to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.

2026-07-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health

This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), are requested to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.

2026-07-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)

National Institutes of Health

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of developmental neuroscience are encouraged to begin to consider applying for this new NOFO.

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)

National Institutes of Health

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of developmental neuroscience are encouraged to begin to consider applying for this new NOFO.

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)

National Institutes of Health

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)

National Institutes of Health

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)

National Institutes of Health

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of integrative neuroscience are encouraged to begin to consider applying for this new NOFO.

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)

National Institutes of Health

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of integrative neuroscience are encouraged to begin to consider applying for this new NOFO.

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)

National Institutes of Health

Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)

2027-03-08

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

National Institutes of Health

The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single piece of new, costly, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of $500,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for submission in CY 2026, consider S10 funding in FYs 2023-2025; for submission in CY 2027, consider S10 funding in FYs 2024-2026; for submission in CY 2028, consider S10 funding in FYs 2025-2027. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $350,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.

2027-06-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

National Institutes of Health

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

2027-06-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

National Institutes of Health

2027-06-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program

National Institutes of Health

The Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program supports resource-limited institutions to develop and strengthen their capacity to conduct rigorous and reproducible biomedical research. Eligible organizations are expected to propose plans based on identified needs in one or more of the following areas: biomedical research environment, sponsored programs administration and a post-award pilot research project program. By supporting research capacity building at resource-limited institutions, the BRE-SPAD program will expand and strengthen the pool of faculty and trainees conducting rigorous biomedical research, and the organizational settings where NIH-funded research is performed.This is a Forecast for a Limited Competition that will invite applications from eligible organizations to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered for funding.

2028-01-27

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program

National Institutes of Health

The Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program supports resource-limited institutions to develop and strengthen their capacity to conduct rigorous and reproducible biomedical research. Eligible organizations are expected to propose plans based on identified needs in one or more of the following areas: biomedical research environment, sponsored programs administration and a post-award pilot research project program. By supporting research capacity building at resource-limited institutions, the BRE-SPAD program will expand and strengthen the pool of faculty and trainees conducting rigorous biomedical research, and the organizational settings where NIH-funded research is performed.This is a Forecast for a Limited Competition that will invite applications from eligible organizations to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered for funding.

2028-01-27

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program

National Institutes of Health

Limited Competition: Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program

researchEnvironmental

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

National Institutes of Health

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

National Institutes of Health

Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources:The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), andThe Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials.The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. NCTN Biobanks support the biobanking operations of the NCTN funded through the Cancer Therapy Evaluation Program (CTEP) and NCORP funded through the Division of Cancer Prevention (DCP). The clinical trials conducted through NCTN and NCORP enroll thousands of patients with adult and childhood cancers each year. NCTN Biobank operations aim to facilitate hypothesis-driven biomarker development and validation, secondary research studies, and broader scientific discovery. Biospecimens collected through harmonized protocols and long-term follow-up across large multi-site clinical trials provide valuable resources for studying disease mechanisms, therapeutic response, and clinical outcomes in different types of cancers.This NOFO will also support the continuation of the EET Biobank, a dedicated resource with a primary focus on meeting the biospecimen banking needs of the ETCTN and other early-phase and experimental clinical trials involving investigational new drugs (INDs). Biospecimens collected from the early phase clinical trials enable validated biomarker assay development, pharmacokinetic and pharmacodynamic studies, investigation of drug action and resistance mechanisms, improved patient stratification, and broader scientific discovery. Unlike the NCTN Biobank, the EET Biobank bridges basic science and clinical applications that enable acceleration of NCI s IND development efforts for effective cancer treatments. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

2026-07-14

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional

National Institutes of Health

The National Human Genome Research Institute (NHGRI) seeks to broaden the types of knowledge, skills, expertise, experience, and perspectives brought to bear in research addressing the ethical, legal and social implications (ELSI) of advances in human genetics or genomics. This Notice of Funding Opportunity (NOFO) solicits UM1 applications from domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years. These organizations are underrepresented among those receiving NHGRI funding for ELSI research. The Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BPAER) Program will support: 1) transdisciplinary ELSI research addressing timely, complex, and understudied topics, 2) the establishment of research teams that include representatives from relevant communities who are affected by and have an interest in the proposed research, 3) research capacity building to develop, conduct and sustain ELSI research, and 4) workforce development opportunities for early career scholars, research team members, and other research project staff. Transdisciplinary ELSI research projects require involvement from two or more fields of knowledge and use of multiple research approaches. Relevant communities must be actively and meaningfully involved on ELSI research teams across all phases of proposed research projects. Research capacity building plans must be informed by a needs assessment. Given the complex structure, a strategic management plan, evaluation plan, and sustainability plan are required to ensure successful completion of the program.

Up to $850K

2026-08-02

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional

National Institutes of Health

Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional

2026-08-02

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

National Institutes of Health

Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

2028-01-07